Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06909825Phase 2Active Not Recruiting

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Role: lead

NCT06402331Phase 2Active Not Recruiting

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Role: lead

NCT03746431Phase 1Terminated

A Phase 1 Study of [225Ac]-FPI-1434 Injection

Role: lead

NCT05219500Phase 2Active Not Recruiting

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Role: lead

NCT05363605Phase 1Terminated

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Role: lead

All 5 trials loaded